Clinical Response to Low-dose Omalizumab Treatment in Chronic Spontaneous Urticaria: A Retrospective Study of 179 Patients

Omalizumab is effective in chronic spontaneous urticaria unresponsive to antihistamines. Of the licensed dosing schedules, Korean patients prefer a low dose, of 150 mg/month, for financial reasons. However, real-world experiences of low-dose omalizumab consumption have not been reported. The aim of...

Full description

Bibliographic Details

Published in:	Acta Dermato-Venereologica
Main Authors:	Min Jae Kim, Bo Ri Kim, Sae Hoon Kim, Yoon Seok Chang, Sang Woong Youn
Format:	Article
Language:	English
Published:	Medical Journals Sweden 2023-08-01
Subjects:	allergy chronic urticaria comorbidities omalizumab severity smoking
Online Access:	https://medicaljournalssweden.se/actadv/article/view/11627